Edit
Clementia
http://www.clementiapharma.com/Last activity: 06.11.2019
Active - Reference to Ipsen
Clementia is a privately-held, clinical stage biotechnology company dedicated to the development and commercialization of treatments for people living with rare diseases. Clementia exploits the use of novel Retinoic acid receptor gamma agonists (RARγ) to address diseases of heterotopic ossification, including Fibrodysplasia Ossificans Progressiva.
Location: Canada, Quebec, Montreal
Employees: 11-50
Total raised: $92.5M
Founded date: 2011
Investors 3
| Date | Name | Website |
| - | RA Capital... | racap.com |
| - | EcoR1 Capi... | ecor1cap.c... |
| - | BDC | bdc.ca/ |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 23.06.2015 | - | $60M | - |
| 05.01.2015 | Series A | $10M | - |
| 10.01.2014 | Series A | $22.5M | - |
Mentions in press and media 9
| Date | Title | Description |
| 06.11.2019 | BDC spinout Amplitude Ventures closes half of newly-launched $200 million health fund | Amplitude Ventures, a Montréal-headquartered investment firm focused on health and the life sciences sectors has announced the launch of a targeted $200 million CAD venture fund. The firm is a spin-out of the Business Development Bank of Ca... |
| 07.08.2017 | Clementia Pharmaceuticals Raises US$10M; Launches IPO | Clementia Pharmaceuticals (NASDAQ: CMTA), a Montreal, Canada-based developer of a drug to treat fibrodysplasia ossificans progressiva, raised US$10m in pre IPO funding. In March 2017, in the wake of Clementia Pharmaceuticals’ initial public... |
| 03.08.2017 | Term Sheet — Thursday, Aug. 3 | MARKDOWNS AGAIN After we wrote about mutual fund markdowns to Uber’s share price, a few readers wrote in asking how mutual funds determine their markdowns. Paid Content What you need to know about growing cyberattacks From ExtraHop • This i... |
| 23.06.2015 | Clementia Pharmaceuticals Completes US$60m Mezzanine Round of Financing | Clementia Pharmaceuticals, Inc., a Montreal, Quebec, Canada-based clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people living with rare diseases, completed a U.S. $60m mezzanine ... |
| 23.06.2015 | Clementia bags $60M to push a repurposed Roche drug through Phase II | Canadian biotech Clementia Pharmaceuticals raised $60 million in mezzanine cash to help it fashion a once-failed Roche ($RHHBY) drug into a promising treatment for a rare disease. VC giant New Enterprise Associates stepped in to lead the la... |
| 05.01.2015 | Clementia Pharmaceuticals Raises $10M | MONTREAL, CANADA, Clementia Pharmaceuticals, Inc. today announced that it has secured an additional $10 million from current investors. >> Click here for more funding data on Clementia Pharmaceuticals >> To export Clementia ... |
| 05.01.2015 | Clementia Pharmaceuticals Secures Additional $10M in Series A Funding | Clementia Pharmaceuticals, Inc., a Montreal, Quebec, Canada-based clinical-stage biopharmaceutical company, secured an additional $10m in Series A funding. The round was led by OrbiMed Advisors with participation from BDC Venture Capital. T... |
| 10.01.2014 | Clementia Pharmaceuticals Closes $22.5M Series A Financing | Clementia Pharmaceuticals, Inc., a Dorval, Quebec, Canada-based clinical stage biotechnology company dedicated to the development and delivery of treatments for people living with rare diseases, closed a $22.5m Series A financing. The round... |
| 09.01.2014 | Clementia Pharmaceuticals Closes $22.5M | MONTREAL, QC, Privately held clinical stage biotechnology company dedicated to the development and delivery of treatments for people living with rare diseases, announced today the closing of a $22.5 million Series A financing led by OrbiM... |